<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="108.0" right="539.88" top="705.52"><span x0="108.0" y0="705.52" x1="539.88" style="x0: 108.0; x1: 116.66; y0: 705.52; y1: 717.52; width: 8.66; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">Kremer and Leino (2004) highlight another feature of health public goods: namely, many </span></div><div left="72.0" right="502.44" top="677.92"><span x0="72.0" y0="677.92" x1="502.44" style="x0: 72.0; x1: 78.0; y0: 677.92; y1: 689.92; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">of these goods possess more local benefits at the national or regional levels.  Often, these </span></div><div left="72.0" right="511.44" top="650.32"><span x0="72.0" y0="650.32" x1="511.44" style="x0: 72.0; x1: 75.34; y0: 650.32; y1: 662.32; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">localized benefits are jointly produced with the global benefits &#8211; e.g., treating an infectious </span></div><div left="72.0" right="536.74" top="622.72"><span x0="72.0" y0="622.72" x1="536.74" style="x0: 72.0; x1: 77.33; y0: 622.72; y1: 634.72; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">epidemic provides training to indigenous healthcare workers.  Such complementary benefits can </span></div><div left="72.0" right="522.36" top="595.12"><span x0="72.0" y0="595.12" x1="522.36" style="x0: 72.0; x1: 81.34; y0: 595.12; y1: 607.12; width: 9.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">motivate or crowd-in host-country actions.  When a disease is region- or geoclimatic-specific </span></div><div left="72.0" right="531.48" top="567.52"><span x0="72.0" y0="567.52" x1="531.48" style="x0: 72.0; x1: 76.0; y0: 567.52; y1: 579.52; width: 4.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">(e.g., some malaria strains), benefits from fighting the disease may have little global spillovers, </span></div><div left="72.0" right="522.48" top="539.92"><span x0="72.0" y0="539.92" x1="522.48" style="x0: 72.0; x1: 75.34; y0: 539.92; y1: 551.92; width: 3.34; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">leading to the need for nation- or region-based health institutions.  As such, assistance from a </span></div><div left="72.0" right="493.32" top="512.32"><span x0="72.0" y0="512.32" x1="493.32" style="x0: 72.0; x1: 76.0; y0: 512.32; y1: 524.32; width: 4.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">regional, rather than a global, institution may be more appropriate.  This is an appeal to </span></div><div left="72.0" right="518.16" top="484.72"><span x0="72.0" y0="484.72" x1="518.16" style="x0: 72.0; x1: 76.67; y0: 484.72; y1: 496.72; width: 4.67; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">subsidiarity by not necessarily equating health contingencies with GPGs and global-directed </span></div><div left="72.0" right="522.12" top="457.12"><span x0="72.0" y0="457.12" x1="522.12" style="x0: 72.0; x1: 77.33; y0: 457.12; y1: 469.12; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">action.  Nevertheless, Kremer (2006) recognizes that combating communicable diseases with </span></div><div left="72.0" right="540.84" top="429.52"><span x0="72.0" y0="429.52" x1="540.84" style="x0: 72.0; x1: 80.66; y0: 429.52; y1: 441.52; width: 8.66; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">wide spillover ranges are GPGs, as is vaccine-based eradication of polio or other global diseases. </span></div><div left="108.0" right="535.8" top="401.92"><span x0="108.0" y0="401.92" x1="535.8" style="x0: 108.0; x1: 116.66; y0: 401.92; y1: 413.92; width: 8.66; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">A final distinguishing feature of health GPGs involves the wide variety of impure public </span></div><div left="72.0" right="342.36" top="374.32"><span x0="72.0" y0="374.32" x1="342.36" style="x0: 72.0; x1: 78.0; y0: 374.32; y1: 386.32; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">goods owing to rivalry and excludability considerations.</span><span x0="342.84" y0="381.05" x1="350.94" style="x0: 342.84; x1: 346.86; y0: 381.05; y1: 389.09; width: 4.02; font-size: 8.04; font-family: TNXFRR+TimesNewRomanPSMT;">57</span><span x0="357.0" y0="374.32" x1="494.16" style="x0: 357.0; x1: 363.67; y0: 374.32; y1: 386.32; width: 6.67; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">For example, internet-based </span></div><div left="72.0" right="526.32" top="346.72"><span x0="72.0" y0="346.72" x1="526.32" style="x0: 72.0; x1: 78.0; y0: 346.72; y1: 358.72; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">diagnostic procedures possess club good elements due to crowding and exclusion that provide </span></div><div left="72.0" right="519.12" top="319.12"><span x0="72.0" y0="319.12" x1="519.12" style="x0: 72.0; x1: 76.67; y0: 319.12; y1: 331.12; width: 4.67; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">subscription funding possibilities.  Knowledge gained from clinical trials or research may be </span></div><div left="72.0" right="535.08" top="291.52"><span x0="72.0" y0="291.52" x1="535.08" style="x0: 72.0; x1: 77.33; y0: 291.52; y1: 303.52; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">excludable.  Elite hospitals that treat patients worldwide offer health private goods to those who </span></div><div left="72.0" right="219.24" top="263.92"><span x0="72.0" y0="263.92" x1="219.24" style="x0: 72.0; x1: 77.33; y0: 263.92; y1: 275.92; width: 5.33; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">can afford the best specialists. </span></div><div left="72.0" right="93.0" top="208.72"><span x0="72.0" y0="208.72" x1="93.0" style="x0: 72.0; x1: 78.0; y0: 208.72; y1: 220.72; width: 6.0; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">9.2  </span><span x0="93.0" y0="208.72" x1="296.4" style="x0: 93.0; x1: 97.0; y0: 208.72; y1: 220.72; width: 4.0; font-size: 12.0; font-family: IUNRTN+TimesNewRomanPS-ItalicMT;">Infectious versus Non-infectious Diseases </span></div><div left="72.0" right="524.64" top="181.12"><span x0="72.0" y0="181.12" x1="524.64" style="x0: 72.0; x1: 80.66; y0: 181.12; y1: 193.12; width: 8.66; font-size: 12.0; font-family: TNXFRR+TimesNewRomanPSMT;">Healthcare concerns differ greatly between rich and poor countries.  That difference is starkly </span></div><div left="72.0" right="78.48" top="138.89"><span x0="72.0" y0="138.89" x1="78.48" style="x0: 72.0; x1: 75.24; y0: 138.89; y1: 145.37; width: 3.24; font-size: 6.48; font-family: TNXFRR+TimesNewRomanPSMT;">57</span><span x0="81.0" y0="133.26" x1="520.76" style="x0: 81.0; x1: 87.09; y0: 133.26; y1: 143.22; width: 6.09; font-size: 9.96; font-family: TNXFRR+TimesNewRomanPSMT;">Today, there is almost no literature that tests for the strategic interactions among governments with respect to health GPGs.  A notable exception is by Kyle, Ridley, and Zhang (2017) who study how medical research funding in other countries for infectious and parasitic diseases respond to changes in US government funding for the same diseases.  Their study finds that greater US funding significantly reduced research funding elsewhere on these diseases.  This is a clear free-riding result, indicative of pure publicness.  Also, those funding reductions are shown to be repurposed to other diseases.  The article applies an interesting identification strategy using the composition of the US Congressional appropriations committee and NIH budgets to isolate influence of changes in US funding. </span></div></body></html>